"The U.S. Food and Drug Administration today granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa&rsqu"...
Side effects associated with Brevital Sodium are extensions of pharmacologic effects and include:
Nausea, emesis, abdominal pain, and liver function tests abnormal
Other adverse reactions include pain at injection site, salivation, headache, and rhinitis
For medical advice about adverse reactions contact your medical professional. To report SUSPECTED ADVERSE REACTIONS, contact JHP at 1-866-923-2547 or MEDWATCH at 1800-FDA-1088 (1-800-332-1088) or http://www.fda.gov/medwatch/.
Drug Abuse And Dependence
Controlled Substance-Brevital Sodium is a Schedule IV drug.
Brevital Sodium may be habit-forming.
Read the Brevital Sodium (methohexital sodium for injection) Side Effects Center for a complete guide to possible side effects
Prior chronic administration of barbiturates or phenytoin (e.g. for seizure disorder) appears to reduce the effectiveness of Brevital Sodium. Barbiturates may influence the metabolism of other concomitantly used drugs, such as phenytoin, halothane, anticoagulants, corticosteroids, ethyl alcohol, and propylene glycol-containing solutions.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/7/2014
Additional Brevital Sodium Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.